<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313476361</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313476361</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lee</surname><given-names>JY</given-names></name>
<xref ref-type="corresp" rid="corresp1-0961203313476361"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Luc</surname><given-names>S</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Greenblatt</surname><given-names>DJ</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Kalish</surname><given-names>R</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>McAlindon</surname><given-names>TE</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0961203313476361">Tufts Medical Center, Boston, MA</aff>
<author-notes>
<corresp id="corresp1-0961203313476361">Ji Yeon Lee, Division of Rheumatology, Tufts Medical Center, Boston, MA, 800 Washington St. box #406 Boston, MA 02111, USA. Email: <email>agnesljy@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>541</fpage>
<lpage>542</lpage>
<history>
<date date-type="received"><day>1</day><month>10</month><year>2012</year></date>
<date date-type="accepted"><day>29</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<custom-meta-wrap>
<custom-meta>
<meta-name>edited-state</meta-name>
<meta-value>corrected-proof</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Sir,</p>
<p>We describe the possible association of blood hydroxychloroquine (HCQ) level and renal function in patients with systemic lupus erythematosus (SLE) from a pilot study at a single academic rheumatology clinic. HCQ is a critically important medication in the management of patients with SLE as it is safe and effective in preventing flares.<sup><xref ref-type="bibr" rid="bibr1-0961203313476361">1</xref></sup> However, the pharmacokinetics of HCQ are not fully understood, and only a few studies have explored the factors associated with variation in blood HCQ concentration in individual patients.</p>
<p>We conducted a cross-sectional study to explore the relationship of various factors to blood HCQ levels in SLE patients. The study population consisted of 30 patients with SLE, who were seen between December 2009 and April 2010 in the Rheumatology clinic at Tufts Medical Center in Boston, Massachusetts. Inclusion criteria were any SLE patients aged 18 years or older who fulfilled the American College of Rheumatology criteria, had been on oral HCQ for at least two months and were willing to provide blood samples. Written informed consent was obtained from each participant. The study was approved by the Institutional Review Board of Tufts Medical Center. Whole blood HCQ levels were quantified by high-performance liquid chromatography (HPLC) with fluorescence detection.</p>
<p>From a total of 30 participants, three were excluded in data analysis due to undetectable HCQ levels. The characteristics of subjects are listed in <xref ref-type="table" rid="table1-0961203313476361">Table 1</xref>. Four out of 27 had abnormal estimated glomerular filtration rate (GFR) ranging from 3 to 71 mL/min/1.73m<sup>2</sup> using the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation.<sup><xref ref-type="bibr" rid="bibr2-0961203313476361">2</xref></sup> Self-completed questionnaires indicated relative quiescence of disease activity. Ethnicity, age, gender, smoking status, HCQ dose, HCQ dose per weight, abnormal liver function tests were not associated with blood HCQ level. However, GFR was significantly related to blood HCQ level(<italic>r</italic> = –0.558, <italic>p</italic> = .002 by Spearman correlation). When subjects were dichotomized into two groups of normal and abnormal GFR, two groups were significantly different from HCQ level (<italic>p</italic> = .002) (<xref ref-type="table" rid="table1-0961203313476361">Table 1</xref>, <xref ref-type="fig" rid="fig1-0961203313476361">Figure 1</xref>).
<fig id="fig1-0961203313476361" position="float"><label>Figure 1</label><caption><p>Blood hydroxychloroquine level by GFR status.</p></caption><graphic xlink:href="10.1177_0961203313476361-fig1.tif"/>
</fig>
<table-wrap id="table1-0961203313476361" position="float"><label>Table 1</label><caption><p>Subject characteristics</p></caption>
<graphic alternate-form-of="table1-0961203313476361" xlink:href="10.1177_0961203313476361-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Total N = 27 Mean ± SD or N(%)</th>
<th>Normal GFR N = 23 Mean ± SD or N(%)</th>
<th>Abnormal GFR N = 4 Mean ± SD or N(%)</th>
<th>p</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age, years</td>
<td>41.5 ± 13.5</td>
<td>39.9 ± 12.1</td>
<td>50.8 ± 19.3</td>
<td>0.14<sup>a</sup></td>
</tr>
<tr>
<td>Weight, kg</td>
<td>68.4 ± 15.2</td>
<td>69.0 ± 15.8</td>
<td>64.8 ± 12.7</td>
<td>0.62<sup>a</sup></td>
</tr>
<tr>
<td>Female, <italic>n</italic></td>
<td>25 (93)</td>
<td>21 (91.3)</td>
<td>4 (100)</td>
<td>0.54<sup>b</sup></td>
</tr>
<tr>
<td>Ethnicity, <italic>n</italic></td>
<td/>
<td/>
<td/>
<td rowspan="5">0.85<sup>b</sup></td>
</tr>
<tr>
<td> White</td>
<td>12 (44.4)</td>
<td>10 (43.5)</td>
<td>2 (50)</td>
</tr>
<tr>
<td> Black</td>
<td>4 (14.8)</td>
<td>3 (13)</td>
<td>1 (25)</td>
</tr>
<tr>
<td> Asian</td>
<td>9 (33.4)</td>
<td>8 (34.8)</td>
<td>1 (25)</td>
</tr>
<tr>
<td> Latino</td>
<td>2 (7.4)</td>
<td>2 (8.7)</td>
<td>0</td>
</tr>
<tr>
<td>Smokers, <italic>n</italic></td>
<td>3 (11.1)</td>
<td>3 (13)</td>
<td>0</td>
<td>0.44<sup>b</sup></td>
</tr>
<tr>
<td>Mean HCQ dose, mg/kg</td>
<td>4.5 ± 1.7</td>
<td>4.5 ± 1.7</td>
<td>4.6 ± 1.3</td>
<td>0.92<sup>a</sup></td>
</tr>
<tr>
<td>Mean HCQ concentration, ng/ml</td>
<td>532.1 ± 484.8</td>
<td>386.4 ± 245.4</td>
<td>1369.8 ± 705.0</td>
<td>0.002<sup>c</sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313476361"><p>Comparisons are made by <sup>a</sup>t-test, <sup>b</sup>chi-square test, <sup>c</sup>Wilcoxon rank sum test.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Our study was one of the few studies that measured blood HCQ level in SLE patients,<sup><xref ref-type="bibr" rid="bibr3-0961203313476361">3</xref>,<xref ref-type="bibr" rid="bibr4-0961203313476361">4</xref></sup> and even though we were not able to correlate HCQ level with most of the variables in this small stable SLE group, we did find a relationship between renal function and the level of blood HCQ. Though our study is limited by its lack of power and its inability to determine medication compliance, the finding of high blood HCQ level in patients with decreased renal function may have an important clinical significance. Although HCQ is mainly excreted in urine<sup><xref ref-type="bibr" rid="bibr5-0961203313476361">5</xref></sup> there currently is no guideline for dose adjustment in SLE patients with renal dysfunction. Previous studies suggested that significant impairment of renal function could result in increased tissue retention of HCQ and constitute a risk factor for retinopathy.<sup><xref ref-type="bibr" rid="bibr6-0961203313476361">6</xref></sup> In addition renal failure was suggested as a predisposing factor for neuromyotoxicity among patients taking HCQ.<sup><xref ref-type="bibr" rid="bibr7-0961203313476361">7</xref></sup> Therefore, further studies are needed in SLE patients with renal insufficiency to confirm our findings and to examine the relationship of blood HCQ level, drug efficacy, and toxicity.</p>
</body>
<back>
<sec id="sec1-0961203313476361"><title>Funding</title>
<p>Dr Lee was supported by T32 HS000060 from Agency for Healthcare Research and Quality. This work was also supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health [Grant UL1 RR025752].</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313476361"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsakonas</surname><given-names>E</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Esdaile</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus</article-title>. <source><italic>The Canadian Hydroxychloroquine Study Group.</italic> Lupus</source> <year>1998</year>; <volume>7</volume>: <fpage>80</fpage>–<lpage>85</lpage>.</citation></ref>
<ref id="bibr2-0961203313476361"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>A new equation to estimate glomerular filtration rate</article-title>. <source>Ann Intern Med</source> <year>2009</year>; <volume>150</volume>: <fpage>604</fpage>–<lpage>612</lpage>.</citation></ref>
<ref id="bibr3-0961203313476361"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name><name><surname>Amoura</surname><given-names>Z</given-names></name><name><surname>Hulot</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>3284</fpage>–<lpage>3290</lpage>.</citation></ref>
<ref id="bibr4-0961203313476361"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name><name><surname>Galicier</surname><given-names>L</given-names></name><name><surname>Aumaitre</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study)</article-title>. <source>Ann Rheum Dis</source> <year>2012</year>; <volume>Nov 10</volume>.</citation></ref>
<ref id="bibr5-0961203313476361"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furst</surname><given-names>DE</given-names></name></person-group>. <article-title>Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases</article-title>. <source>Lupus</source> <year>1996</year>; <volume>5 Suppl 1</volume>: <fpage>S11</fpage>–<lpage>5</lpage>.</citation></ref>
<ref id="bibr6-0961203313476361"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>HN</given-names></name></person-group>. <article-title>Ocular safety of hydroxychloroquine sulfate (Plaquenil)</article-title>. <source>South Med J</source> <year>1992</year>; <volume>85</volume>: <fpage>274</fpage>–<lpage>279</lpage>.</citation></ref>
<ref id="bibr7-0961203313476361"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>MJ</given-names></name><name><surname>Ang</surname><given-names>LC</given-names></name></person-group>. <article-title>Hydroxychloroquine neuromyotoxicity</article-title>. <source>J Rheumatol</source> <year>2000</year>; <volume>27</volume>: <fpage>2927</fpage>–<lpage>2931</lpage>.</citation></ref>
</ref-list>
</back>
</article>